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Background: Gastrointestinal manifestations are frequently encountered in cystic fibrosis patients. Gastroparesis evidenced by a variety of
diagnostic methods has been described in patients with cystic fibrosis, predominantly in children and in individuals with advanced lung disease.
The presence of gastroparesis in adult patients with different degrees of lung involvement and its response to the acute and chronic administration
of macrolides have not been reported.
Methods: Using the University of Florida Cystic Fibrosis database we identified symptomatic patients who had gastroparesis confirmed by a
prolonged half-time during gastric emptying scintigraphy.
Results: Of 86 cystic fibrosis patients, periodically followed in our institution, we found five who had classical symptoms and prolonged gastric
emptying half-time. Age 25.2±8 years, 80% females, BMI 22±9 kg/m2, HbA1c 5.8±0.6 g/dl, FEV1 53.2±15% of predicted. Gastric emptying
half-time was 191.4±91.4 min (range 100–300 min) and decreased to 12.2±6 min (range 5–20 min) after IV administration of erythromycin
(p=0.043). Patients were followed up for 3±2.1 years. All patients but one, who was taking opiods, had good clinical response to PO macrolides.
Conclusions: Gastroparesis occurs in patients with cystic fibrosis, even in patients with relatively preserved lung function and in those without
cystic-fibrosis related diabetes. Macrolides may be an effective therapy in cystic fibrosis patients with gastroparesis when administered acutely or
chronically.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Gastroparesis; Erythromycin; Gastric emptying scintigraphy1. Background
Gastrointestinal complaints are commonly reported by cystic
fibrosis patients and are generally related to exocrine pancreatic
insufficiency, gastroesophageal reflux disease, distal intestinal
obstruction syndrome, hepatobiliary tract involvement and
complications related to previous abdominal surgeries.☆ The authors have no significant conflicts of interest with any companies or
organization whose products or services may be discussed in this article.
⁎ Corresponding author. Health Science Center, 1600 SWArcher Road, Room
M452, PO Box 100225, Gainesville, Florida, 32610-0225, United States.
Fax: +1 352 392 0821.
E-mail address: Adriano.Tonelli@medicine.ufl.edu (A.R. Tonelli).
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doi:10.1016/j.jcf.2009.02.001Gastrointestinal dysmotility, and more specifically gastropar-
esis, have been described in association with cystic fibrosis
predominantly in children and advanced lung disease. The
published data is scant and confusing, as patients of different ages
and degree of disease were included. In addition, diverse
diagnostic methods were used to measure gastric emptying,
including: 1) marker dilution technique, 2) electrogastrography,
3) epigastric impedance recording and 4) gastric emptying
scintigraphy (using differentmeals and protocols). An appropriate
correlation among these differentmodalities for assessing delayed
gastric emptying is lacking [1], and of all the available tests,
gastric emptying scintigraphy with 99mTc-sulfur colloid bound to
solid food is the most accepted one for diagnosing gastroparesis.d by Elsevier B.V. All rights reserved.
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emptying scintigraphy, as well as for the chronic treatment of
cystic fibrosis associated gastroparesis. We report the response
to macrolide treatment in 5 patients with symptomatic
gastroparesis confirmed by a prolonged gastric emptying half-
time, who had different degrees of lung disease and body mass
index.
2. Methods
We reviewed the charts of cystic fibrosis patients using the
University of Florida Cystic Fibrosis database. We identified
patients who had gastrointestinal symptoms and a nuclear
gastric emptying scintigraphy reflecting gastroparesis.
The University of Florida gastric emptying study methodol-
ogy is as follows: The patient was administered one whole
scrambled egg meal with 2 pieces of white bread/one slab of
butter and 50–100 cm3 of water. This meal is labeled with 0.5–
1.0 mCi of Tc-99m sulfur colloid. After administration of the
meal, the patients were imaged continuously for 120 min at
1 min per frame using either a single-headed gamma camera,
equipped with a low-energy, high resolution collimator,
positioned in the left anterior oblique position to minimize the
effects of varying gastric attenuation on quantitation of the
gastric emptying rate or a dual-headed camera similarly
positioned (the latter with calculation of geometric mean
activity). A simple linear fit was applied to the rate of gastric
emptying with calculation of the gastric emptying half-time
(normal=45–90 min). At 80 min into the examination, the
patients were administered 250 mg of IV erythromycin, infused
over 20 min, with calculation of the new post-erythromycin
half-time. Before the study, patients had to stop for 48 h all
medications known to affect gastric emptying. Serum glucose
was measured before the test and was considered appropriate for
the performance of the study if less than 140 mg/dl.
One patient underwent Antroduodenal Manometry, via a
fluoroscopically placed catheter (with leads in the antrum and
small intestine), that measures luminal pressure patterns
(amplitude and frequency of antral pressure and characteristics
of the activity front of the migrating motor complex). After a 7-
hour baseline manometric recording and a 4-hour fed state a
therapeutic portion was performed with erythromycin 250 mg
IV, azithromycin 250 mg IV and octreotide 50 μg SQ.
Gastroparesis is characterized by a decreased frequency of
antral contractions and low or normal fasting migrating motorTable 1
Baseline characteristics of cystic fibrosis patients included in the study.
Pt Age Sex Genetic mutation BMI (kg/m2) HbA1c DM Tx
1 38 F ΔF508/ΔF508 37.4 5.2%
2 19 F Sweat Cl− 110 mEq/l 20.5 5.8%
3 21 F ΔF508/E60X 19.6 6% on insulin gargline 5
4 21 F ΔF508/ΔF508 13.2 6.6% on insulin gargline
5 27 M ΔF508/2184 insA 19.2 5.4%
F: female, M: male, BMI: body mass index, DM Tx: treatment for diabetes mellitu
GE 1/2: gastric emptying half-time.complexes. This test is predominantly used for excluding small
intestinal dysmotilities [13].
Demographic characteristics, genetic mutation, body mass
index, spirometric values and HbA1c were recorded. All of
these patients were followed by a gastroenterologist at our
institution. All of them received treatment with macrolides in an
elixir form. The medications were modified according to
response. Initial symptoms and response to treatment were
recorded. Patients were followed for different intervals of time.
We used Wilcoxon Signed Rank test to compare the gastric
emptying half time before and after the IV administration of
erythromycin. When appropriate we provide numeric values as
mean±standard deviation.
3. Results
Of the total of 86 active patients in our clinic (those who
were regularly followed-up at our institution), five individuals
with the classic symptoms of gastroparesis confirmed by gastric
emptying scintigraphy were included. Mean age was 25.2±
7.7 years, four patients were females, four patients had typical
cystic fibrosis associated mutations and the remaining patient
had a positive sweat chloride test. Mean body mass index was
21.98±9.1 kg/m2. Nearly all patients complained of nausea,
vomiting, bloating, early satiety and abdominal pain. Two of
five patients had cystic fibrosis-related diabetes and were
receiving insulin. Mean HbA1c was 5.8±0.55 g/dl and FEV1
was 53.18±15% of predicted. Three patients were receiving
azithromycin 500 mg/day 3 times a week that they stopped 48 h
before the test. Before the gastric emptying half time the serum
glucose was 105.8±17 mg/dl. Mean gastric emptying half-time
was 191.4±91.4 min (range 100–300 min) and decreased to
12.2±5.8 min (range 5–20 min) after IV erythromycin
(p=0.043) (Table 1 and Fig. 1).
One patient (patient #1) also underwent Gastroduodenal
Manometry that showed decreased antral contractions and normal
small bowel activity. Both erythromycin and azithromycin
induced adequate antral contractions.
Patients were followed for 3±2.1 years (range 1–6 years).
All patients were treated with erythromycin elixir (200 mg three
times a day with meals) or azithromycin elixir (400 mg once a
day) as part of a protocol used at our institution. To assess the
clinical effect to macrolide therapy we define four possible
types of clinical response: 1) excellent, 2) very good, 3) good
and 4) no response. Four of five patients noted a significantFEV1 (% of pred) GE 1/2 time (min) GE 1/2 time after
erythromycin (min)
73 300 5
44.8 270 16
Units/day 44.1 179 10
18 Unit/day 65.3 100 20
38.7 108 10
s, FEV1: forced expiratory volume in 1 s, % of pred: percentage of predicted,
Fig. 1. Gastric emptying scintigraphy with decay correction. In patient 1 the gastric emptying half-time was more than 300 min. IV metoclopramide (Reglan®) was
given at 75 min and IVerythromycin administered at 95 min, decreasing the half-time to 60 and 5 min respectively. In patient 2 gastric emptying half-time was 270 min
that decreased to 16 min after the administration of IV erythromycin at 82 min of the test. In patient 3 the half-time decreased from 179 min to 10 min after
administration of IVerythromycin at 76 min of the test. In patient 4 the half-time decreased from 100 min to 20 min after administration of IVerythromycin at 76 min of
the test. In patient 5 the half-time decreased from 108 min to 10 min after the administration of IVerythromycin at 75 min of the study. T1/2: gastric emptying half-time,
Erythro: erythromycin.
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clinical visit to the gastroenterologist after macrolide therapy
was instituted. One patient did not experience any relief of
symptoms either initially or during the follow up, but was
receiving high doses of narcotics for epigastric pain attributed to
chronic pancreatitis. At the end of the follow-up, one patient
scored the effectiveness of therapy as excellent (while receiving
azithromycin), one patient as very good (while on azithromy-
cin), two patients as good (one treated with azithromycin and
the other with erythromycin, the patient receiving azithromycin
required the addition of bethanecol after several months of
treatment, as she had return of symptoms) and the last of the
patients had no response (while receiving erythromycin). Of
interest is that all five patients with gastroparesis had associated
gastrointestinal conditions such as gastroesophageal reflux
disease (3 of 5 patients) or pancreatic insufficiency (5 of 5
patients).
4. Discussion
In this study we described the presence of gastroparesis in 5
out of 86 adult patients with cystic fibrosis who are periodically
followed at our Cystic Fibrosis Care Center. Gastroparesis was
identified in patients with a wide variety of BMI, HbA1c and
degree of respiratory involvement (measured by FEV1). All five
patients with gastroparesis had pancreatic insufficiency and
three had gastroesophageal reflux disease.
It is relevant that all patients had dramatic improvements
on the gastric emptying half-time with IV administration of
erythromycin and all the patients except one experienced
different degrees of symptomatic relief during the follow-up.
The patient that did not notice any benefit was concomitantly
receiving large doses of opioids for severe epigastric pain
attributed to chronic pancreatitis. Four patients are currently
treated with azithromycin and one of them required the addition
of bethanechol as she noticed return of some gastrointestinal
symptoms after several months of receiving treatment with
erythromycin. None of the patients with gastroparesis received
metoclopramide as maintenance therapy, because of concerns
regarding extrapyramidal side effects and risk of tardive
dyskinesia.
Gastroparesis should be suspected in cystic fibrosis patients
that experience symptoms associated with gastric retention
(nausea, vomiting, bloating, early satiety, abdominal pain and
heartburn). The abnormality should be confirmed by objective
evidence of delayed gastric emptying in the absence of
mechanical obstruction, since there is a poor correlation between
clinical manifestations and gastric emptying abnormalities [2,3].
Multiple diagnostic modalities using a variety of protocols
have provided conflicting results regarding the presence of
gastric dysmotility in patients with cystic fibrosis. Studies have
described normal [4–6], delayed [2,7–10] or accelerated [11,12]
gastric emptying rates. Gastroparesis has been described in
cystic fibrosis predominantly in children and patients with
advanced lung disease.
Liquid–solid gastric emptying scintigraphy in cystic fibrosis
patients before lung transplant (mean 1.6 years before) revealedthat 67% and 13% of the patients had delayed gastric emptying
for solids (half-time 160.86±59.21 min) and liquids, respec-
tively; showing a high prevalence of solid gastroparesis in end-
stage cystic fibrosis patients. In addition, gastric emptying times
for solids and liquids were significantly prolonged after lung
transplantation [2]. In contrast, in relatively healthy cystic
fibrosis patients the solid phase gastric emptying half-time was
significantly faster when compared with matched controls,
probably due to relatively higher energy intake in patients with
cystic fibrosis [11].
The diverse results found in these studies may be explained
by different ages, disease severity (respiratory and pancreatic),
diagnostic methodologies used (solid gastric emptying studies
are more sensible and this is the current state of care), and the
multi-factorial origin of gastroparesis [2,9,18–26].
The identification of gastroparesis in patients with cystic
fibrosis is relevant as it 1) generates significant discomfort, 2)
may affect the absorption and/or effect of medications such as
pancreatic enzyme replacement since patients with slow gastric
emptying have lower activity of pancreatic replacement therapy
[4], 3) may affect timing of medications, as pancreatic enzyme
microspheres may empty earlier than food, following the liquid
phase of gastric emptying [13], and 4) may cause unpredictable
gastric emptying and therefore affect glycemic control in cystic
fibrosis-related diabetes [3].
There are no data regarding management of cystic fibrosis
related gastroparesis. Treatment for gastroparesis in general
includes 1) dietary modifications (frequent small and low fat
meals, maintain normal glucemia and avoid medications that
further delay gastrointestinal motility), 2) gastric emptying
stimulants (metroclopramide, domperidone, macrolides and
bethanechol), 3) invasive approaches (botulinum injection in
the pylorus to reduce tone, venting gastrostomies, and enteral
and parenteral nutrition), 4) psychological interventions, and 5)
alternative devices (gastric electrical stimulation and TENS:
transcutaneous electrical nerve stimulation) [14].
Of the gastric emptying stimulants, erythromycin is the
current first line therapy for gastroparesis. It is a powerful
stimulator of antral contractions through activation of motilin
receptors. It better accelerates gastric emptying and controls
symptoms when compared with other available alternatives
[15]. It has been shown to improve solid gastric emptying in
patients with gastroparesis (diabetic or idiopathic) acutely (IV
administration) and after 4 weeks of therapy (oral administra-
tion) [16].
A relevant problem with erythromycin is that it may increase
the risk of sudden death particularly in patients receiving CYP3A
inhibitors by prolonging cardiac repolarization and predisposing
patients to torsades de pointes [17]. Another macrolide,
azithromycin, has minimal effect on the cardiac repolarization
and only minimally interacts with CYP3A inhibitors [3].
In summary, we observed symptomatic gastroparesis in a wide
variety of patients with cystic fibrosis. No association was found
between gastric emptying half-time and BMI, presence of
diabetes and severity of respiratory disease. All our patients had
pancreatic insufficiency and were receiving pancreatic replace-
ment therapy. The exact mechanism involved in the development
197A.R. Tonelli et al. / Journal of Cystic Fibrosis 8 (2009) 193–197of gastroparesis in our patients is unclear. We noticed a good
initial symptomatic response with erythromycin, but over the
course of months some symptoms returned and the medication
was switched to azithromycin with good response.
Our current report is limited by the retrospective nature of the
examination, and by the small sample size (n=5). A prospective
study comparing CF patients of different ages and degrees of
respiratory disease, including individuals with cystic fibrosis
related diabetes mellitus, using the state of the art diagnostic
modalities for gastroparesis is necessary but unlikely to occur as
patients would have to be exposed to radiation or relatively
invasive procedures. In addition, as the great majority of cystic
fibrosis patients receive treatment with azithromycin thrice a
week, it would be interesting to prospectively compare this
intervention with the daily use of 400 mg of azithromycin elixir
on the control of symptoms of gastroparesis and occurrence of
adverse effects.
5. Conclusions
Gastroparesis occurs in patients with cystic fibrosis, even in
patients with relatively preserved lung function and in those
without cystic fibrosis-related diabetes. Intravenous erythromycin
significantly reduced the gastric emptying half time. Chronic
macrolide antibiotics may be an effective treatment in cystic
fibrosis patients with gastroparesis.
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